medigraphic.com

2014, Number 3

<< Back Next >>

Rev Fac Med UNAM 2014; 57 (3)

Molecular basis of sepsis Abstract

Carrillo ER, Tapia JJ, Peña PCA, Kim KMJ, Jaime LÁR, Montalvo JEE

Language: Spanish
References: 59
Page: 9-21
PDF size: 455.99 Kb.


ABSTRACT

Sepsis continues to be a primary cause of high mortality and morbidity in critically ill patients. Despite constant growth in dedicated basic investigation and numerous clinical studies, no remarkable developments have been made for effective and innovative therapies. The physiologic disorders induced by sepsis are primarily due to the overwhelming immune response to invading pathogens rather than the direct effects caused by the pathogen.
Sepsis, understood as the systemic inflammatory response to infection is characterized by the unregulated production of proinflammatory cytokines. These mediators collectively lead to multiple organ failure and eventually to death. In this context, the role of inflammation in the physiopathology of sepsis, though not fully understood, is of critical importance. This review provides a perspective of the most current understandings of the molecular mechanisms during sepsis, which may provide an attempt to understand the nature of this unregulated response of the immune systems during sepsis.


REFERENCES

  1. Geroulanos S, Douka ET. Historical perspective of the word “sepsis”. Intensive Care Med. 2006;32:2077.

  2. Vincent JL, Abraham E. The last 100 years of sepsis. Am J Resp Crit Care Med. 2006;173:256-63.

  3. Schottmueller H. Wesen und Behandlung der Sepsis (The nature and therapy of sepsis). Inn Med. 1914;31:257-80 (In German).

  4. Kumar A, Parrillo J. Shock: classification, pathophysiology, and approach to management. In: Parrillo JE, Dellinger RP, editors. Critical care medicine: principles of diagnosis and management in the adult. 3rd edition. Philadelphia: Mosby Elsevier; 2008. P. 377-422.

  5. Cai B, Deitch EA, Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm. 2010;2010:642462.

  6. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-50.

  7. Riedemann NC, Ward PA. Anti-inflammatory strategies for the treatment of sepsis. Expert Opin Biol Ther. 2003; 3:339-50.

  8. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, et al. Association of FNT2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA. 1999;282:561-8.

  9. Van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock. 1995;3:1-12.

  10. Moshage H. Cytokines and the hepatic acute phase response. J Pathol. 1997;181: 257-66.

  11. Beasley D, Schwartz JH, Brenner BM. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest. 1991;87:602-8.

  12. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-51.

  13. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. CHEST. 1997;112:321S-329S.

  14. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988;81:1162-72.

  15. Van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990;322:1622-27.

  16. Kast RE. Tumor necrosis factor has positive and negative self-regulatory feedback cycles centered around cAMP. Int J Immunopharmacol. 2000;22:1001-6.

  17. Cinel I, Dellinger RP. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis. 2007;20:345-52.

  18. Van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:32-43.

  19. Creagh EM, O’Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 2006;27:352-7.

  20. Granucci F, Foti M, Ricciardi-Castagnoli P. Dendritic cell biology. Adv Immunol. 2005;88:193-233.

  21. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med. 2007;84:712-25.

  22. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock. 2006;26:430-7.

  23. Paterson HM, Murphy TJ, Purcell EJ, Shelley O, Kriynovich SJ, Lien E, et al. Injury primes the innate immune system for enhanced toll-like receptor reactivity. J Immunol. 2003;171:1473-83.

  24. Ayscough KR, Gourlay CW. The actin cytoskeleton: a key regulator of apoptosis and aging. Nat Rev Mol Cell Biol. 2005;6:583-9.

  25. Fischer U, Jänicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ. 2003;10:76-100.

  26. Nakae H, Endo S, Inada K, Takakuma T, Kasai T, Yoshida M. Serum complement levels and severity of sepsis. Res Commun Chem Pathol Pharmacol. 1994;84:189-95.

  27. Gerard C. Complement C5a in the sepsis syndrome – too much of a good thing? N Engl J Med. 2003;348:167-9.

  28. Kildsgaard J, Hollmann TJ, Matthews KW, Bian K, Murad F, Wetsel RA. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective antiinflammatory role for C3a in endotoxin-shock. J Immunol. 2000;165:5406-9.

  29. Francis K, Lewis BM, Akatsu H, Monk PN, Cain SA, Scanion MF, et al. Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immu- ne molecule releases hormones involved in the control of inflammation. FASEB J. 2003;17:2266-8.

  30. Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, Lu KT, Guo RF, et al. Complement-induced impairment of innate immunity during sepsis. J Immunol. 2002;169:3223-31.

  31. Flieri MA, Schreiber H, Huber-Lang MS. The role of complement, C5a and its receptors in sepsis and multiorgan dysfunction syndrome. JInvest Surg. 2006;19:255-65.

  32. Reidemann NC, Guo RF, Laudes IJ, Keller K, Sarma VJ, Padgaonkar V, et al. C5a receptor and thymocyte apoptosis in sepsis. FASEB J. 2002;16:887-8.

  33. Frierl MA, Rittirsch D, Chen AJ, Nadeau BA, Day DE, Sarma JV, et al. The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. PLoS ONE. 2008;3:e2560.

  34. Laudes IJ, Chu JC, Sikranth S, Huber-Lang MS, Guo RF, Riedemann N, et al. Anti-c5a ameliorates coagulation/ fibrinolytic protein in changes in a rat model of sepsis. Am J Pathol. 2002;160:1867-75.

  35. Niederbichler AD, Hoesel LM, Westfall MV, Gao H, Ipaktchi KR, Sun L, et al. An essential role for complement C5a in the pathogenesis of sepsis cardiac dysfunction. J Exp Med. 2006;203:53-61.

  36. Shi X, Leng L, Wang T, Wang W, Du X, Li j, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006; 25:595-606.

  37. Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S, et al. An anti-inflammatory function for the complement anaphilatoxin C5a-binding protein, C5L2. J Biol Chem. 2005;280:39677-80.

  38. Chen NJ, Mirtsos C, Suh D, Lu YC, Lin WJ, McKerlie C, et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature. 2007;446:203-7.

  39. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Resp Cell Mol Biol. 2000;22:401-4.

  40. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004;114:321-7.

  41. Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, et al. Interleukine-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost. 1996;76:738-42.

  42. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukine-1. Proc Nat Acad Sci USA. 1986;83:4533-7.

  43. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344 699-709.

  44. Maugeri N, Brambilla M, Camera M, Carbone A, Tremoli E, Donati MB, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost. 2006;4:1323-30.

  45. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuilemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res. 2006;118:205-12.

  46. Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation basedon current understanding of pathophysiology. Am Med. 2004;36:41-49.

  47. Esmon CT. The protein C pathway. CHEST. 2003;124: 26S-32S.

  48. Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199-203.

  49. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-2.

  50. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, et al. Dendritic cell PAR-1-S1P3 signalling couples coagulation and inlammation. Nature. 2008;452:654-8.

  51. Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, et al. “Role reversal” for the receptor PAR- 1 in sepsis induced vascular damage. Nature Immunol. 2007;8:1303-12.

  52. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994;269:26486-91.

  53. Ito T, Kawahara K, Nakamura T, Yamada S, Nakamura T, Abeyama K, , et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost. 2007;5:109-16.

  54. Goldberger G, Thomas ML, Tack BF, Williams J, Colten HR, Abraham GN. NH2-terminal structure and cleavage of guinea pig pro-C3, the precursor of the third complement component. J Biol Chem. 1981;256:12617-9.

  55. Thoman ML, Meuth JL, Morgan EL, Weigle WO, Hugli TE. C3d-K a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation. J Immunol. 1984;133:2629-33.

  56. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and inhibitor of fibrinolysis. Immunol Rev. 2001;180:162-7.

  57. Wojta J, Kaun C, Zorn G, Ghannadan M, Hauswirth AW, Sperr WR, et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood. 2002;100:517-23.

  58. Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, Rosenfeld SI. C5 chemotatic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest. 1979;63:147-50.

  59. Krarup A, Wallis R, Presanis JS, Gal P, Sim RB. Simultaneous activation of complement and coagulation by MBLassociated serine protease 2. PLoS ONE. 2007;2:e623.




2020     |     www.medigraphic.com